Evommune (EVMN) Total Liabilities (2024 - 2026)

Evommune (EVMN) posted quarterly Total Liabilities of $17.9 million for Q1 2026, down 7.64% quarter-over-quarter from $19.4 million in Q4 2025.

Evommune (EVMN) Total Liabilities (2024 - 2026) Analysis & Trends

Evommune (EVMN) has reported Total Liabilities for 3 consecutive years, with $17.9 million the latest figure, recorded in Q1 2026.

In Q1 2026, Total Liabilities changed N/A year-over-year to $17.9 million; the TTM figure through Mar 2026 stood at $17.9 million (changed N/A YoY), while the FY2025 annual figure was $19.4 million, down 32.04% from the prior year.
Total Liabilities slipped to $17.9 million in Q1 2026 per EVMN's latest filing, from $19.4 million in the prior quarter.
Across five years, Total Liabilities topped out at $28.5 million in Q4 2024 and bottomed at $10.7 million in Q3 2025.
Historically, Total Liabilities has averaged $19.1 million across 3 years, with a median of $18.6 million in 2025.
On a YoY basis, Total Liabilities climbed as much as 32.04% in 2025 and fell as far as 32.04% in 2025.
Evommune's Total Liabilities stood at $28.5 million in 2024, then plunged by 32.04% to $19.4 million in 2025, then dropped by 7.64% to $17.9 million in 2026.
Business Quant data shows EVMN's Total Liabilities at $17.9 million in Q1 2026, $19.4 million in Q4 2025, and $10.7 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Liabilities (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	7.18 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	10.02 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.62 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	1.72 Bn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	4.00 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	7.02 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	10.03 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	4.20 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	1.35 Bn
10	Evommune	531.53 Mn	330.73 Mn	-	24.36 Mn

Download Data